Rilparencel (Renal Autologous Cell Therapy-REACT ®) for Chronic Kidney Disease and Type 1 and 2 Diabetes: Phase 2 Trial Design Evaluating Bilateral Kidney Dosing and Re-Dosing Triggers
CONCLUSION: This multicenter phase 2 RCT is designed to investigate the efficacy and safety of rilparencel with bilateral kidney dosing and comparing two injection schedules with the potential of preserving or improving kidney function and delaying kidney disease progression among patients with Stages 3a-4 CKD with diabetes.PMID:38423000 | DOI:10.1159/000537942
Source: American Journal of Nephrology - Category: Urology & Nephrology Authors: Joseph Stavas Arnold L Silva Thomas D Wooldridge Ahmed Aqeel Theodore Saad Rachita Prakash George Bakris Source Type: research
More News: Chronic Kidney Disease | Diabetes | Diabetes Type 1 | Endocrinology | Urology & Nephrology